IBJNews

Lilly chases Novo in insulin race

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. announced positive results for an experimental insulin at the annual American Diabetes Association conference in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.

Novo announced more encouraging data about its super-long-acting insulin degludec, which it has submitted to the U.S. Food and Drug Adminstration for approval.

Degludec proved as effective as Lantus, the leading long-acting insulin, at reducing blood sugar levels and led to fewer incidents of overnight hyperglycemia, the company said.

Novo is trying to grab more of the $5 billion in sales Lantus enjoys.

Lilly and its development partner Boehringer Ingelheim GmbH announced results at the conference about a long-acting insulin glargine they are developing to compete with Lantus. According to the Associated Press, the drug, known as LY2605541, was slightly better at reducing blood sugar levels and inducing weight loss for Type 1 diabetics, compared with Lantus. Results for Type 2 diabetics were about the same with either drug in the mid-stage clinical trial.

Lilly and Boehringer also announced new clinical trial results for their drug Tradjenta, which hit the market in the United States and Europe last year.

Lilly is the No. 3 player in diabetes, behind Novo and France-based Sanofi Aventisu SA, the maker of Lantus. But with Lantus’ patent expiring in 2014, Lilly could bump up to the No. 2 spot, according to projections by Jefferies & Co. analyst Jeffrey Holford.

Holford expects Lilly’s diabetes pipeline to produce $1.2 billion in new revenue by 2017, and for its existing diabetes products to add at least another $1 billion in annual revenue by then.

That represents compounded annual growth of more than 8 percent. But Holford still expects Novo to grow faster, at about 11 percent compounded annually.

"We expect the key diabetes brands and markets to exhibit sustainable high-single-digit growth," Holford recently wrote to investors. With Western populations aging and emerging nations adopting Western diets, he expects diabetes mediciations will reach a whopping $54 billion in sales by 2020.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. In reality, Lilly is maintaining profit by cutting costs such as Indiana/US citizen IT workers by a significant amount with their Tata Indian consulting connection, increasing Indian H1B's at Lillys Indiana locations significantly and offshoring to India high paying Indiana jobs to cut costs and increase profit at the expense of U.S. workers.

  2. I think perhaps there is legal precedence here in that the laws were intended for family farms, not pig processing plants on a huge scale. There has to be a way to squash this judges judgment and overrule her dumb judgement. Perhaps she should be required to live in one of those neighbors houses for a month next to the farm to see how she likes it. She is there to protect the people, not the corporations.

  3. http://www.omafra.gov.on.ca/english/engineer/facts/03-111.htm Corporate farms are not farms, they are indeed factories on a huge scale. The amount of waste and unhealthy smells are environmentally unsafe. If they want to do this, they should be forced to buy a boundary around their farm at a premium price to the homeowners and landowners that have to eat, sleep, and live in a cesspool of pig smells. Imagine living in a house that smells like a restroom all the time. Does the state really believe they should take the side of these corporate farms and not protect Indiana citizens. Perhaps justifiable they should force all the management of the farms to live on the farm itself and not live probably far away from there. Would be interesting to investigate the housing locations of those working at and managing the corporate farms.

  4. downtown in the same area as O'malia's. 350 E New York. Not sure that another one could survive. I agree a Target is needed d'town. Downtown Philly even had a 3 story Kmart for its downtown residents.

  5. Indy-area residents... most of you have no idea how AMAZING Aurelio's is. South of Chicago was a cool pizza place... but it pales in comparison to the heavenly thin crust Aurelio's pizza. Their deep dish is pretty good too. My waistline is expanding just thinking about this!

ADVERTISEMENT